Novo Nordisk directors and the firm's controlling shareholder failed to reach an agreement on the future composition of the board.

Moves follow disagreement with Danish drugmaker’s majority shareholder the Novo Nordisk Foundation

Novo Nordisk directors and the firm's controlling shareholder failed to reach an agreement on the future composition of the board.